首页 > 最新文献

Current Opinion in Ophthalmology最新文献

英文 中文
Leber hereditary optic neuropathy gene therapy. Leber 遗传性视神经病变基因疗法。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2023-12-21 DOI: 10.1097/icu.0000000000001028
Byron L Lam
To discuss relevant clinical outcomes, challenges, and future opportunities of gene therapy in Leber hereditary optic neuropathy (LHON).
讨论基因疗法治疗 Leber 遗传性视神经病变 (LHON) 的相关临床结果、挑战和未来机遇。
{"title":"Leber hereditary optic neuropathy gene therapy.","authors":"Byron L Lam","doi":"10.1097/icu.0000000000001028","DOIUrl":"https://doi.org/10.1097/icu.0000000000001028","url":null,"abstract":"To discuss relevant clinical outcomes, challenges, and future opportunities of gene therapy in Leber hereditary optic neuropathy (LHON).","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":"70 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138826880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genes as drugs for glaucoma: latest advances. 基因作为治疗青光眼的药物:最新进展。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2023-12-21 DOI: 10.1097/icu.0000000000001025
Teresa Borrás, Michelle Stepankoff, John Danias
To provide the latest advances on the future use of gene therapy for the treatment of glaucoma.
介绍未来使用基因疗法治疗青光眼的最新进展。
{"title":"Genes as drugs for glaucoma: latest advances.","authors":"Teresa Borrás, Michelle Stepankoff, John Danias","doi":"10.1097/icu.0000000000001025","DOIUrl":"https://doi.org/10.1097/icu.0000000000001025","url":null,"abstract":"To provide the latest advances on the future use of gene therapy for the treatment of glaucoma.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":"17 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138826527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glaucoma surgical procedures under development. 正在开发的青光眼手术程序。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2023-12-15 DOI: 10.1097/icu.0000000000001020
Ariana M Levin, Arsham Sheybani
Rapid innovation in glaucoma surgery is expanding surgical options in the angle, subconjunctival space, and supraciliary space.
青光眼手术的快速创新扩大了房角、结膜下间隙和睫状上间隙的手术选择范围。
{"title":"Glaucoma surgical procedures under development.","authors":"Ariana M Levin, Arsham Sheybani","doi":"10.1097/icu.0000000000001020","DOIUrl":"https://doi.org/10.1097/icu.0000000000001020","url":null,"abstract":"Rapid innovation in glaucoma surgery is expanding surgical options in the angle, subconjunctival space, and supraciliary space.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":"3 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138743716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuro-ophthalmic manifestations of Ehlers-Danlos syndrome. 埃勒斯-丹洛斯综合征的神经眼科表现。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2023-11-01 Epub Date: 2023-08-30 DOI: 10.1097/ICU.0000000000001002
Sruti S Rachapudi, Noor A Laylani, Pamela A Davila-Siliezar, Andrew G Lee

Purpose of review: To review the neuro-ophthalmic manifestations of Ehlers-Danlos syndrome (EDS).

Recent findings: Ehlers-Danlos syndrome (EDS) is a rare genetic disorder with an estimated prevalence of 1 in 5000 individuals, but its true prevalence may be underestimated because of variable clinical presentations and limited awareness among healthcare professionals. The neuro-ophthalmic features of EDS may be difficult to recognize in context but new molecular genetic testing is now available for identification of specific subtypes of EDS.

Summary: Ophthalmic manifestations of EDS include loss of vision and double vision (strabismus), high myopia, retinal detachment, and blue sclera. The vascular subtype of EDS can present as a carotid-cavernous fistula, intracranial aneurysm, or arterial dissection.

综述目的:综述埃勒斯-丹洛斯综合征(EDS)的神经眼科表现。最近的研究结果:埃勒斯-达洛斯综合征是一种罕见的遗传性疾病,估计患病率为1/5000,但由于临床表现多变,医疗专业人员的知识有限,其真实患病率可能被低估。EDS的神经眼科特征可能很难在上下文中识别,但新的分子遗传学测试现在可用于识别EDS的特定亚型。总结:EDS的眼科表现包括视力丧失和复视(斜视)、高度近视、视网膜脱离和蓝色巩膜。EDS的血管亚型可表现为颈动脉海绵窦瘘、颅内动脉瘤或动脉夹层。
{"title":"Neuro-ophthalmic manifestations of Ehlers-Danlos syndrome.","authors":"Sruti S Rachapudi,&nbsp;Noor A Laylani,&nbsp;Pamela A Davila-Siliezar,&nbsp;Andrew G Lee","doi":"10.1097/ICU.0000000000001002","DOIUrl":"10.1097/ICU.0000000000001002","url":null,"abstract":"<p><strong>Purpose of review: </strong>To review the neuro-ophthalmic manifestations of Ehlers-Danlos syndrome (EDS).</p><p><strong>Recent findings: </strong>Ehlers-Danlos syndrome (EDS) is a rare genetic disorder with an estimated prevalence of 1 in 5000 individuals, but its true prevalence may be underestimated because of variable clinical presentations and limited awareness among healthcare professionals. The neuro-ophthalmic features of EDS may be difficult to recognize in context but new molecular genetic testing is now available for identification of specific subtypes of EDS.</p><p><strong>Summary: </strong>Ophthalmic manifestations of EDS include loss of vision and double vision (strabismus), high myopia, retinal detachment, and blue sclera. The vascular subtype of EDS can present as a carotid-cavernous fistula, intracranial aneurysm, or arterial dissection.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":"34 6","pages":"476-480"},"PeriodicalIF":3.7,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41173221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial introductions 编辑介绍
2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2023-11-01 DOI: 10.1097/icu.0000000000000993
Current Opinion in Ophthalmology was launched in 1990. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of Ophthalmology is divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue. SECTION EDITORS Dean CestariDean CestariDr Cestari completed residencies in both Neurology and Ophthalmology at the Cornell University Medical College's New York Presbyterian Hospital, as well as fellowship training in neuro-ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School, Massachusetts, USA. He is one of approximately 10 physicians in the United States who is board certified by both the American Board of Ophthalmology and the American Board of Psychiatry & Neurology. Dr Cestari joined the full-time faculty of Mass. Eye and Ear, a primary teaching hospital for Harvard Medical School, in 2006 and currently holds the rank of Associate Professor of Ophthalmology, Harvard Medical School. He is very involved in medical education and is the Director of the Clinical Fellowship program at The Massachusetts Eye and Ear Infirmary. His efforts as a clinician-scientist focus on the evaluation and treatment of patients who present with neuro-ophthalmic disease. He is also very involved in the medical and surgical treatment of thyroid eye disease with strabismus and diplopia. He just published a surgical textbook entitled, “Learning Strabismus Surgery, A Case Based Approach.” He supervises clinical fellows, second year residents and visiting medical students and performs adult strabismus surgery and mentors second year residents in the operating theater. Dr Cestari's translational research is focused on developing a rodent model for ischemic optic neuropathy and central retinal artery occlusion. Once this is accomplished, his team will begin to evaluate the safety and efficacy of various novel neuro-protective agents that can be used to preserve and restore vision affected by vascular occlusion. Additionally, he is working with a team of engineers from MIT and Harvard University to design and build an implantable device to restore ocular motility to denervated extra-ocular muscles from nerve palsys. John GonzalesJohn GonzalesDr Gonzales is an Associate Professor of Ophthalmology at the Francis I. Proctor Foundation at the University of California, San Francisco, USA specializing in uveitis and medical cornea. He is supported by an early career award from the National Institutes of Health – National Eye Institute to study the spectrum of keratoconjunctivitis sicca in Sjögren's syndrome utilizing the Sjögren's International Collaborative Clinical Alliance (SICCA) cohort. Dr Gonzales is also pur
《当代眼科意见》创刊于1990年。它是一系列成功的评论期刊之一,其独特的格式旨在提供许多主要期刊中提出的文献的系统和批判性评估。眼科领域分为九个部分,每年审查一次。每个章节都有一个章节编辑,他是该领域的权威,负责确定当时最重要的主题。在这里,我们很高兴地介绍本刊的栏目编辑。Dean Cestari博士在康奈尔大学医学院纽约长老会医院完成了神经病学和眼科的住院医师培训,并在美国马萨诸塞州哈佛医学院马萨诸塞州眼耳医院接受了神经眼科的奖学金培训。他是美国大约10位获得美国眼科委员会和美国精神病学和神经病学委员会认证的医生之一。塞斯塔里博士成为了麻省理工学院的全职教员。眼耳医院是哈佛医学院的主要教学医院,于2006年成立,目前担任哈佛医学院眼科副教授。他非常热衷于医学教育,是马萨诸塞州眼耳医院临床奖学金项目的主任。作为一名临床医生兼科学家,他的工作重点是评估和治疗患有神经眼病的患者。他还积极参与甲状腺眼病伴斜视和复视的内科和外科治疗。他刚刚出版了一本外科教科书,名为《学习斜视手术,基于案例的方法》。他监督临床研究员,二年级住院医师和访问医学生,并进行成人斜视手术,并在手术室指导二年级住院医师。Cestari博士的转化研究重点是开发缺血性视神经病变和视网膜中央动脉闭塞的啮齿动物模型。一旦这项工作完成,他的团队将开始评估各种新型神经保护剂的安全性和有效性,这些保护剂可用于保护和恢复受血管闭塞影响的视力。此外,他正在与来自麻省理工学院和哈佛大学的工程师团队合作,设计并制造一种植入式装置,以恢复神经麻痹的失神经眼外肌的眼球运动。John Gonzales博士是美国加州大学旧金山分校Francis I. Proctor基金会的眼科副教授,专门研究葡萄膜炎和医用角膜。他得到了美国国立卫生研究院国家眼科研究所的早期职业奖的支持,利用Sjögren的国际临床合作联盟(sicca)队列研究Sjögren综合征中干燥性角膜结膜炎的频谱。Gonzales博士也在研究免疫正常个体巨细胞病毒前葡萄膜炎的治疗策略。Gonzales博士的兴趣也扩展到眼部肿瘤学,特别是原发性玻璃体视网膜淋巴瘤,他对临床特征如何与淋巴细胞增殖相关的突变以及对化疗药物的耐药性相关感兴趣。冈萨雷斯博士是《当代眼科学观点》栏目编辑,也是普罗克托基金会葡萄膜炎研究项目主任。
{"title":"Editorial introductions","authors":"","doi":"10.1097/icu.0000000000000993","DOIUrl":"https://doi.org/10.1097/icu.0000000000000993","url":null,"abstract":"Current Opinion in Ophthalmology was launched in 1990. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of Ophthalmology is divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue. SECTION EDITORS Dean CestariDean CestariDr Cestari completed residencies in both Neurology and Ophthalmology at the Cornell University Medical College's New York Presbyterian Hospital, as well as fellowship training in neuro-ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School, Massachusetts, USA. He is one of approximately 10 physicians in the United States who is board certified by both the American Board of Ophthalmology and the American Board of Psychiatry & Neurology. Dr Cestari joined the full-time faculty of Mass. Eye and Ear, a primary teaching hospital for Harvard Medical School, in 2006 and currently holds the rank of Associate Professor of Ophthalmology, Harvard Medical School. He is very involved in medical education and is the Director of the Clinical Fellowship program at The Massachusetts Eye and Ear Infirmary. His efforts as a clinician-scientist focus on the evaluation and treatment of patients who present with neuro-ophthalmic disease. He is also very involved in the medical and surgical treatment of thyroid eye disease with strabismus and diplopia. He just published a surgical textbook entitled, “Learning Strabismus Surgery, A Case Based Approach.” He supervises clinical fellows, second year residents and visiting medical students and performs adult strabismus surgery and mentors second year residents in the operating theater. Dr Cestari's translational research is focused on developing a rodent model for ischemic optic neuropathy and central retinal artery occlusion. Once this is accomplished, his team will begin to evaluate the safety and efficacy of various novel neuro-protective agents that can be used to preserve and restore vision affected by vascular occlusion. Additionally, he is working with a team of engineers from MIT and Harvard University to design and build an implantable device to restore ocular motility to denervated extra-ocular muscles from nerve palsys. John GonzalesJohn GonzalesDr Gonzales is an Associate Professor of Ophthalmology at the Francis I. Proctor Foundation at the University of California, San Francisco, USA specializing in uveitis and medical cornea. He is supported by an early career award from the National Institutes of Health – National Eye Institute to study the spectrum of keratoconjunctivitis sicca in Sjögren's syndrome utilizing the Sjögren's International Collaborative Clinical Alliance (SICCA) cohort. Dr Gonzales is also pur","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":"55 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136371349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ocular features in Williams-Beuren syndrome: a review of the literature. Williams-Beuren综合征的眼部特征:文献综述。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2023-11-01 Epub Date: 2023-08-17 DOI: 10.1097/ICU.0000000000000990
Marco Nassisi, Claudia Mainetti, Andrea Aretti, Andrea Sperti, Valeria Nicotra, Berardo Rinaldi, Federica Natacci, Maria Francesca Bedeschi, Francesco Viola

Purpose of review: The current review will discuss the pathophysiology, work-up and clinical relevance of the ocular phenotype in Williams-Beuren syndrome in detail.

Recent findings: Few case reports, case series and retrospective studies reported the ophthalmic features in Williams-Beuren syndrome, focusing on specific aspects of the ocular involvement. Recently, novel retinal findings have been described in association with the disease.

Summary: Numerous ocular features have been described in Williams-Beuren syndrome. Some of them, such as the stellate pattern of the iris or the retinal arteriolar tortuosity may be helpful for the diagnosis but have no significant clinical implications; others, such as strabismus and refractive errors require early treatment to reduce the risk of irreversible visual impairment. Finally, some features, such as a broad foveal pit and thinner retina still have unknown significance and require further longitudinal and multimodal studies.

综述目的:本综述将详细讨论Williams-Beuren综合征眼部表型的病理生理学、检查和临床相关性。最近的发现:很少有病例报告、病例系列和回顾性研究报道Williams-Beuren综合征的眼科特征,重点是眼部受累的特定方面。最近,新的视网膜发现被描述为与该疾病有关。摘要:Williams-Beuren综合征有许多眼部特征。其中一些,如虹膜的星状图案或视网膜小动脉弯曲可能有助于诊断,但没有显著的临床意义;其他如斜视和屈光不正需要早期治疗,以降低不可逆视觉损伤的风险。最后,一些特征,如宽阔的中央凹和较薄的视网膜,仍然具有未知的意义,需要进一步的纵向和多模式研究。
{"title":"Ocular features in Williams-Beuren syndrome: a review of the literature.","authors":"Marco Nassisi,&nbsp;Claudia Mainetti,&nbsp;Andrea Aretti,&nbsp;Andrea Sperti,&nbsp;Valeria Nicotra,&nbsp;Berardo Rinaldi,&nbsp;Federica Natacci,&nbsp;Maria Francesca Bedeschi,&nbsp;Francesco Viola","doi":"10.1097/ICU.0000000000000990","DOIUrl":"10.1097/ICU.0000000000000990","url":null,"abstract":"<p><strong>Purpose of review: </strong>The current review will discuss the pathophysiology, work-up and clinical relevance of the ocular phenotype in Williams-Beuren syndrome in detail.</p><p><strong>Recent findings: </strong>Few case reports, case series and retrospective studies reported the ophthalmic features in Williams-Beuren syndrome, focusing on specific aspects of the ocular involvement. Recently, novel retinal findings have been described in association with the disease.</p><p><strong>Summary: </strong>Numerous ocular features have been described in Williams-Beuren syndrome. Some of them, such as the stellate pattern of the iris or the retinal arteriolar tortuosity may be helpful for the diagnosis but have no significant clinical implications; others, such as strabismus and refractive errors require early treatment to reduce the risk of irreversible visual impairment. Finally, some features, such as a broad foveal pit and thinner retina still have unknown significance and require further longitudinal and multimodal studies.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"514-521"},"PeriodicalIF":3.7,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10011801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diversity, equity and inclusion in ophthalmology. 眼科的多样性、公平性和包容性。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2023-09-01 DOI: 10.1097/ICU.0000000000000970
Ugochi T Aguwa, Basil K Williams, Fasika A Woreta

Purpose of review: Diversity, equity and inclusion (DEI) initiatives in ophthalmology have received increased attention in recent years. This review will highlight disparities, barriers to workforce diversity, as well as current and future efforts to improve DEI in ophthalmology.

Recent findings: Racial, ethnic, socioeconomic and sex disparities exist in vision health and across many ophthalmology subspecialties. The pervasive disparities result from factors such as a lack of access to eye care. In addition, ophthalmology is one of the least diverse specialties at the resident and faculty level. The lack of diversity has also been documented in ophthalmology clinical trials, wherein participant demographics do not reflect the diversity of the U.S. population.

Summary: Addressing social determinants of health including racism and discrimination is necessary to promote equity in vision health. Diversifying the workforce and expanding the representation of marginalized groups in clinical research are also paramount. Supporting existing programmes and creating new ones focusing on improving workforce diversity and reducing eye care disparities are essential to ensure equity in vision health for all Americans.

综述目的:近年来,眼科的多样性、公平性和包容性(DEI)倡议受到越来越多的关注。这篇综述将强调差异,劳动力多样性的障碍,以及目前和未来的努力,以提高DEI在眼科。最近的研究发现:种族、民族、社会经济和性别差异存在于视力健康和许多眼科亚专科。这种普遍存在的差距是由于缺乏获得眼科护理的机会等因素造成的。此外,眼科是住院医师和教师水平上多样化程度最低的专业之一。缺乏多样性也被记录在眼科临床试验中,其中参与者的人口统计数据并不能反映美国人口的多样性。摘要:解决包括种族主义和歧视在内的健康社会决定因素是促进视力健康公平的必要条件。使劳动力多样化和扩大边缘化群体在临床研究中的代表性也至关重要。支持现有方案并创建新的方案,重点是改善劳动力多样性和缩小眼科保健差距,这对于确保所有美国人在视力健康方面的公平至关重要。
{"title":"Diversity, equity and inclusion in ophthalmology.","authors":"Ugochi T Aguwa,&nbsp;Basil K Williams,&nbsp;Fasika A Woreta","doi":"10.1097/ICU.0000000000000970","DOIUrl":"https://doi.org/10.1097/ICU.0000000000000970","url":null,"abstract":"<p><strong>Purpose of review: </strong>Diversity, equity and inclusion (DEI) initiatives in ophthalmology have received increased attention in recent years. This review will highlight disparities, barriers to workforce diversity, as well as current and future efforts to improve DEI in ophthalmology.</p><p><strong>Recent findings: </strong>Racial, ethnic, socioeconomic and sex disparities exist in vision health and across many ophthalmology subspecialties. The pervasive disparities result from factors such as a lack of access to eye care. In addition, ophthalmology is one of the least diverse specialties at the resident and faculty level. The lack of diversity has also been documented in ophthalmology clinical trials, wherein participant demographics do not reflect the diversity of the U.S. population.</p><p><strong>Summary: </strong>Addressing social determinants of health including racism and discrimination is necessary to promote equity in vision health. Diversifying the workforce and expanding the representation of marginalized groups in clinical research are also paramount. Supporting existing programmes and creating new ones focusing on improving workforce diversity and reducing eye care disparities are essential to ensure equity in vision health for all Americans.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":"34 5","pages":"378-381"},"PeriodicalIF":3.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10356455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Toward safer ophthalmic artificial intelligence via distributed validation on real-world data. 通过对真实世界数据的分布式验证,实现更安全的眼科人工智能。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2023-09-01 DOI: 10.1097/ICU.0000000000000986
Siddharth Nath, Ehsan Rahimy, Ashley Kras, Edward Korot

Purpose of review: The current article provides an overview of the present approaches to algorithm validation, which are variable and largely self-determined, as well as solutions to address inadequacies.

Recent findings: In the last decade alone, numerous machine learning applications have been proposed for ophthalmic diagnosis or disease monitoring. Remarkably, of these, less than 15 have received regulatory approval for implementation into clinical practice. Although there exists a vast pool of structured and relatively clean datasets from which to develop and test algorithms in the computational 'laboratory', real-world validation remains key to allow for safe, equitable, and clinically reliable implementation. Bottlenecks in the validation process stem from a striking paucity of regulatory guidance surrounding safety and performance thresholds, lack of oversight on critical postdeployment monitoring and context-specific recalibration, and inherent complexities of heterogeneous disease states and clinical environments. Implementation of secure, third-party, unbiased, pre and postdeployment validation offers the potential to address existing shortfalls in the validation process.

Summary: Given the criticality of validation to the algorithm pipeline, there is an urgent need for developers, machine learning researchers, and end-user clinicians to devise a consensus approach, allowing for the rapid introduction of safe, equitable, and clinically valid machine learning implementations.

回顾的目的:本文概述了目前算法验证的方法,这些方法是可变的,很大程度上是自决定的,以及解决不足的解决方案。最近的发现:仅在过去十年中,就有许多机器学习应用于眼科诊断或疾病监测。值得注意的是,其中只有不到15项获得了监管部门的批准,可用于临床实践。尽管存在大量结构化且相对干净的数据集,可用于在计算“实验室”中开发和测试算法,但现实世界的验证仍然是实现安全、公平和临床可靠实施的关键。验证过程中的瓶颈源于围绕安全性和性能阈值的监管指导明显缺乏,对关键的部署后监测和针对具体情况的重新校准缺乏监督,以及异质性疾病状态和临床环境的固有复杂性。安全的、第三方的、无偏见的部署前和部署后验证的实现,为解决验证过程中存在的不足提供了可能。摘要:鉴于验证对算法管道的重要性,开发人员、机器学习研究人员和最终用户临床医生迫切需要设计一种共识方法,以允许快速引入安全、公平和临床有效的机器学习实施。
{"title":"Toward safer ophthalmic artificial intelligence via distributed validation on real-world data.","authors":"Siddharth Nath,&nbsp;Ehsan Rahimy,&nbsp;Ashley Kras,&nbsp;Edward Korot","doi":"10.1097/ICU.0000000000000986","DOIUrl":"https://doi.org/10.1097/ICU.0000000000000986","url":null,"abstract":"<p><strong>Purpose of review: </strong>The current article provides an overview of the present approaches to algorithm validation, which are variable and largely self-determined, as well as solutions to address inadequacies.</p><p><strong>Recent findings: </strong>In the last decade alone, numerous machine learning applications have been proposed for ophthalmic diagnosis or disease monitoring. Remarkably, of these, less than 15 have received regulatory approval for implementation into clinical practice. Although there exists a vast pool of structured and relatively clean datasets from which to develop and test algorithms in the computational 'laboratory', real-world validation remains key to allow for safe, equitable, and clinically reliable implementation. Bottlenecks in the validation process stem from a striking paucity of regulatory guidance surrounding safety and performance thresholds, lack of oversight on critical postdeployment monitoring and context-specific recalibration, and inherent complexities of heterogeneous disease states and clinical environments. Implementation of secure, third-party, unbiased, pre and postdeployment validation offers the potential to address existing shortfalls in the validation process.</p><p><strong>Summary: </strong>Given the criticality of validation to the algorithm pipeline, there is an urgent need for developers, machine learning researchers, and end-user clinicians to devise a consensus approach, allowing for the rapid introduction of safe, equitable, and clinically valid machine learning implementations.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":"34 5","pages":"459-463"},"PeriodicalIF":3.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10039563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence enabled smart digital eye wearables. 人工智能支持智能数字眼可穿戴设备。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2023-09-01 DOI: 10.1097/ICU.0000000000000985
Narrendar RaviChandran, Zhen Ling Teo, Daniel S W Ting

Purpose of review: Smart eyewear is a head-worn wearable device that is evolving as the next phase of ubiquitous wearables. Although their applications in healthcare are being explored, they have the potential to revolutionize teleophthalmology care. This review highlights their applications in ophthalmology care and discusses future scope.

Recent findings: Smart eyewear equips advanced sensors, optical displays, and processing capabilities in a wearable form factor. Rapid technological developments and the integration of artificial intelligence are expanding their reach from consumer space to healthcare applications. This review systematically presents their applications in treating and managing eye-related conditions. This includes remote assessments, real-time monitoring, telehealth consultations, and the facilitation of personalized interventions. They also serve as low-vision assistive devices to help visually impaired, and can aid physicians with operational and surgical tasks.

Summary: Wearables such as smart eyewear collects rich, continuous, objective, individual-specific data, which is difficult to obtain in a clinical setting. By leveraging sophisticated data processing and artificial intelligence based algorithms, these data can identify at-risk patients, recognize behavioral patterns, and make timely interventions. They promise cost-effective and personalized treatment for vision impairments in an effort to mitigate the global burden of eye-related conditions and aging.

回顾目的:智能眼镜是一种头戴式可穿戴设备,正在发展成为无处不在的可穿戴设备的下一个阶段。虽然它们在医疗保健方面的应用还在探索中,但它们有可能彻底改变远端眼科护理。本文综述了它们在眼科护理中的应用,并讨论了未来的应用范围。最新发现:智能眼镜配备了先进的传感器、光学显示器和可穿戴形式的处理能力。快速的技术发展和人工智能的集成正在将其范围从消费领域扩展到医疗保健应用领域。这篇综述系统地介绍了它们在治疗和管理眼部相关疾病中的应用。这包括远程评估、实时监测、远程保健咨询和促进个性化干预。它们还可以作为低视力辅助设备来帮助视障人士,并可以帮助医生完成手术和手术任务。摘要:智能眼镜等可穿戴设备收集丰富、连续、客观、个性化的数据,这些数据在临床环境中很难获得。通过利用复杂的数据处理和基于人工智能的算法,这些数据可以识别高危患者,识别行为模式,并及时采取干预措施。他们承诺为视力障碍提供具有成本效益和个性化的治疗,以减轻与眼睛有关的疾病和衰老的全球负担。
{"title":"Artificial intelligence enabled smart digital eye wearables.","authors":"Narrendar RaviChandran,&nbsp;Zhen Ling Teo,&nbsp;Daniel S W Ting","doi":"10.1097/ICU.0000000000000985","DOIUrl":"https://doi.org/10.1097/ICU.0000000000000985","url":null,"abstract":"<p><strong>Purpose of review: </strong>Smart eyewear is a head-worn wearable device that is evolving as the next phase of ubiquitous wearables. Although their applications in healthcare are being explored, they have the potential to revolutionize teleophthalmology care. This review highlights their applications in ophthalmology care and discusses future scope.</p><p><strong>Recent findings: </strong>Smart eyewear equips advanced sensors, optical displays, and processing capabilities in a wearable form factor. Rapid technological developments and the integration of artificial intelligence are expanding their reach from consumer space to healthcare applications. This review systematically presents their applications in treating and managing eye-related conditions. This includes remote assessments, real-time monitoring, telehealth consultations, and the facilitation of personalized interventions. They also serve as low-vision assistive devices to help visually impaired, and can aid physicians with operational and surgical tasks.</p><p><strong>Summary: </strong>Wearables such as smart eyewear collects rich, continuous, objective, individual-specific data, which is difficult to obtain in a clinical setting. By leveraging sophisticated data processing and artificial intelligence based algorithms, these data can identify at-risk patients, recognize behavioral patterns, and make timely interventions. They promise cost-effective and personalized treatment for vision impairments in an effort to mitigate the global burden of eye-related conditions and aging.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":"34 5","pages":"414-421"},"PeriodicalIF":3.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10025853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence for home monitoring devices. 人工智能家庭监控设备。
IF 3.7 2区 医学 Q1 OPHTHALMOLOGY Pub Date : 2023-09-01 DOI: 10.1097/ICU.0000000000000981
Tiarnan D L Keenan, Anat Loewenstein

Purpose of review: Home monitoring in ophthalmology is appropriate for disease stages requiring frequent monitoring or rapid intervention, for example, neovascular age-related macular degeneration (AMD) and glaucoma, where the balance between frequent hospital attendance versus risk of late detection is a constant challenge. Artificial intelligence approaches are well suited to address some challenges of home monitoring.

Recent findings: Ophthalmic data collected at home have included functional (e.g. perimetry), biometric (e.g. intraocular pressure), and imaging [e.g. optical coherence tomography (OCT)] data. Potential advantages include early detection/intervention, convenience, cost, and visual outcomes. Artificial intelligence can assist with home monitoring workflows by handling large data volumes from frequent testing, compensating for test quality, and extracting useful metrics from complex data. Important use cases include machine learning applied to hyperacuity self-testing for detecting neovascular AMD and deep learning applied to OCT data for quantifying retinal fluid.

Summary: Home monitoring of health conditions is useful for chronic diseases requiring rapid intervention or frequent data sampling to decrease risk of irreversible vision loss. Artificial intelligence may facilitate accurate, frequent, large-scale home monitoring, if algorithms are integrated safely into workflows. Clinical trials and economic evaluations are important to demonstrate the value of artificial intelligence-based home monitoring, towards improved visual outcomes.

综述目的:眼科家庭监测适用于需要频繁监测或快速干预的疾病阶段,例如,新生血管性年龄相关性黄斑变性(AMD)和青光眼,在这些疾病阶段,频繁住院与晚期发现风险之间的平衡是一个持续的挑战。人工智能方法非常适合解决家庭监控的一些挑战。最近的发现:在家里收集的眼科数据包括功能(如视野测量)、生物特征(如眼压)和成像(如光学相干断层扫描(OCT))数据。潜在的优势包括早期检测/干预、方便、成本和视觉效果。人工智能可以通过处理来自频繁测试的大量数据、补偿测试质量以及从复杂数据中提取有用的度量来帮助家庭监控工作流程。重要的用例包括用于检测新生血管性AMD的超锐自检的机器学习和用于量化视网膜液的OCT数据的深度学习。摘要:家庭健康状况监测对于需要快速干预或频繁数据采样以降低不可逆视力丧失风险的慢性疾病是有用的。如果将算法安全地集成到工作流程中,人工智能可能会促进准确、频繁、大规模的家庭监控。临床试验和经济评估对于证明基于人工智能的家庭监控在改善视觉效果方面的价值非常重要。
{"title":"Artificial intelligence for home monitoring devices.","authors":"Tiarnan D L Keenan,&nbsp;Anat Loewenstein","doi":"10.1097/ICU.0000000000000981","DOIUrl":"https://doi.org/10.1097/ICU.0000000000000981","url":null,"abstract":"<p><strong>Purpose of review: </strong>Home monitoring in ophthalmology is appropriate for disease stages requiring frequent monitoring or rapid intervention, for example, neovascular age-related macular degeneration (AMD) and glaucoma, where the balance between frequent hospital attendance versus risk of late detection is a constant challenge. Artificial intelligence approaches are well suited to address some challenges of home monitoring.</p><p><strong>Recent findings: </strong>Ophthalmic data collected at home have included functional (e.g. perimetry), biometric (e.g. intraocular pressure), and imaging [e.g. optical coherence tomography (OCT)] data. Potential advantages include early detection/intervention, convenience, cost, and visual outcomes. Artificial intelligence can assist with home monitoring workflows by handling large data volumes from frequent testing, compensating for test quality, and extracting useful metrics from complex data. Important use cases include machine learning applied to hyperacuity self-testing for detecting neovascular AMD and deep learning applied to OCT data for quantifying retinal fluid.</p><p><strong>Summary: </strong>Home monitoring of health conditions is useful for chronic diseases requiring rapid intervention or frequent data sampling to decrease risk of irreversible vision loss. Artificial intelligence may facilitate accurate, frequent, large-scale home monitoring, if algorithms are integrated safely into workflows. Clinical trials and economic evaluations are important to demonstrate the value of artificial intelligence-based home monitoring, towards improved visual outcomes.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":"34 5","pages":"441-448"},"PeriodicalIF":3.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9972489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Opinion in Ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1